Somatic evolution in neoplastic progression and cancer prevention

Carlo Maley, Eva Szabo, Brian J. Reid

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Cancers develop through a process of somatic evolution. Thus, cancer prevention can be viewed as an attempt to change the selective pressures on tissues to either prevent or delay cancer onset. However, chemoprevention efforts have met with mixed success to date. Most of the cancer prevention trials that have failed have been in high risk patients that are either late in progression or have had chronic mutagenic exposures like cigarette smoke. We hypothesize that some of these trials fail because they select for clones that are resistant to the intervention and actually benefit those clones by suppressing their competitors. The evolutionary understanding of neoplastic progression leads to a variety of predictions and prescriptions for cancer prevention: We should be measuring the selective impact of our interventions in order to discover and manage the evolution of resistance. Pre-clinical models with extensive intratumor genetic heterogeneity should be developed to better predict clinical outcomes. Resistance is less likely to develop prior to the evolution of genetic and epigenetic instability. We should develop measures of the dynamics of somatic evolution so that we can develop interventions to slow the process of neoplastic progression. Multidrug cancer prevention cocktails should be developed that require multiple alterations in order for cells to become resistant to the cocktail. Finally, we should develop cancer prevention interventions with the goal of preventing, channeling or managing somatic evolution. Because somatic evolution is at the heart of neoplastic progression, it must be at the heart of how we manage the disease.

Original languageEnglish (US)
Title of host publicationPre-Invasive Disease: Pathogenesis and Clinical Management
PublisherSpringer New York
Pages111-127
Number of pages17
ISBN (Print)9781441966933
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Clonal Evolution
Neoplasms
Clone Cells
Neoplastic Processes
Genetic Heterogeneity
Molecular Evolution
Chemoprevention
Epigenomics
Smoke
Tobacco Products
Prescriptions
Heart Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Maley, C., Szabo, E., & Reid, B. J. (2011). Somatic evolution in neoplastic progression and cancer prevention. In Pre-Invasive Disease: Pathogenesis and Clinical Management (pp. 111-127). Springer New York. https://doi.org/10.1007/978-1-4419-6694-0_7

Somatic evolution in neoplastic progression and cancer prevention. / Maley, Carlo; Szabo, Eva; Reid, Brian J.

Pre-Invasive Disease: Pathogenesis and Clinical Management. Springer New York, 2011. p. 111-127.

Research output: Chapter in Book/Report/Conference proceedingChapter

Maley, C, Szabo, E & Reid, BJ 2011, Somatic evolution in neoplastic progression and cancer prevention. in Pre-Invasive Disease: Pathogenesis and Clinical Management. Springer New York, pp. 111-127. https://doi.org/10.1007/978-1-4419-6694-0_7
Maley C, Szabo E, Reid BJ. Somatic evolution in neoplastic progression and cancer prevention. In Pre-Invasive Disease: Pathogenesis and Clinical Management. Springer New York. 2011. p. 111-127 https://doi.org/10.1007/978-1-4419-6694-0_7
Maley, Carlo ; Szabo, Eva ; Reid, Brian J. / Somatic evolution in neoplastic progression and cancer prevention. Pre-Invasive Disease: Pathogenesis and Clinical Management. Springer New York, 2011. pp. 111-127
@inbook{c1b26cb56a8b48ff837218e74b4fbbd5,
title = "Somatic evolution in neoplastic progression and cancer prevention",
abstract = "Cancers develop through a process of somatic evolution. Thus, cancer prevention can be viewed as an attempt to change the selective pressures on tissues to either prevent or delay cancer onset. However, chemoprevention efforts have met with mixed success to date. Most of the cancer prevention trials that have failed have been in high risk patients that are either late in progression or have had chronic mutagenic exposures like cigarette smoke. We hypothesize that some of these trials fail because they select for clones that are resistant to the intervention and actually benefit those clones by suppressing their competitors. The evolutionary understanding of neoplastic progression leads to a variety of predictions and prescriptions for cancer prevention: We should be measuring the selective impact of our interventions in order to discover and manage the evolution of resistance. Pre-clinical models with extensive intratumor genetic heterogeneity should be developed to better predict clinical outcomes. Resistance is less likely to develop prior to the evolution of genetic and epigenetic instability. We should develop measures of the dynamics of somatic evolution so that we can develop interventions to slow the process of neoplastic progression. Multidrug cancer prevention cocktails should be developed that require multiple alterations in order for cells to become resistant to the cocktail. Finally, we should develop cancer prevention interventions with the goal of preventing, channeling or managing somatic evolution. Because somatic evolution is at the heart of neoplastic progression, it must be at the heart of how we manage the disease.",
author = "Carlo Maley and Eva Szabo and Reid, {Brian J.}",
year = "2011",
doi = "10.1007/978-1-4419-6694-0_7",
language = "English (US)",
isbn = "9781441966933",
pages = "111--127",
booktitle = "Pre-Invasive Disease: Pathogenesis and Clinical Management",
publisher = "Springer New York",

}

TY - CHAP

T1 - Somatic evolution in neoplastic progression and cancer prevention

AU - Maley, Carlo

AU - Szabo, Eva

AU - Reid, Brian J.

PY - 2011

Y1 - 2011

N2 - Cancers develop through a process of somatic evolution. Thus, cancer prevention can be viewed as an attempt to change the selective pressures on tissues to either prevent or delay cancer onset. However, chemoprevention efforts have met with mixed success to date. Most of the cancer prevention trials that have failed have been in high risk patients that are either late in progression or have had chronic mutagenic exposures like cigarette smoke. We hypothesize that some of these trials fail because they select for clones that are resistant to the intervention and actually benefit those clones by suppressing their competitors. The evolutionary understanding of neoplastic progression leads to a variety of predictions and prescriptions for cancer prevention: We should be measuring the selective impact of our interventions in order to discover and manage the evolution of resistance. Pre-clinical models with extensive intratumor genetic heterogeneity should be developed to better predict clinical outcomes. Resistance is less likely to develop prior to the evolution of genetic and epigenetic instability. We should develop measures of the dynamics of somatic evolution so that we can develop interventions to slow the process of neoplastic progression. Multidrug cancer prevention cocktails should be developed that require multiple alterations in order for cells to become resistant to the cocktail. Finally, we should develop cancer prevention interventions with the goal of preventing, channeling or managing somatic evolution. Because somatic evolution is at the heart of neoplastic progression, it must be at the heart of how we manage the disease.

AB - Cancers develop through a process of somatic evolution. Thus, cancer prevention can be viewed as an attempt to change the selective pressures on tissues to either prevent or delay cancer onset. However, chemoprevention efforts have met with mixed success to date. Most of the cancer prevention trials that have failed have been in high risk patients that are either late in progression or have had chronic mutagenic exposures like cigarette smoke. We hypothesize that some of these trials fail because they select for clones that are resistant to the intervention and actually benefit those clones by suppressing their competitors. The evolutionary understanding of neoplastic progression leads to a variety of predictions and prescriptions for cancer prevention: We should be measuring the selective impact of our interventions in order to discover and manage the evolution of resistance. Pre-clinical models with extensive intratumor genetic heterogeneity should be developed to better predict clinical outcomes. Resistance is less likely to develop prior to the evolution of genetic and epigenetic instability. We should develop measures of the dynamics of somatic evolution so that we can develop interventions to slow the process of neoplastic progression. Multidrug cancer prevention cocktails should be developed that require multiple alterations in order for cells to become resistant to the cocktail. Finally, we should develop cancer prevention interventions with the goal of preventing, channeling or managing somatic evolution. Because somatic evolution is at the heart of neoplastic progression, it must be at the heart of how we manage the disease.

UR - http://www.scopus.com/inward/record.url?scp=84872788029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872788029&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-6694-0_7

DO - 10.1007/978-1-4419-6694-0_7

M3 - Chapter

AN - SCOPUS:84872788029

SN - 9781441966933

SP - 111

EP - 127

BT - Pre-Invasive Disease: Pathogenesis and Clinical Management

PB - Springer New York

ER -